BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-55
SponsorParc de Salut Mar

About this trial

Endocrine therapy is the mainstay of adjuvant therapy in premenopausal women with hormone receptive-positive (HR+) breast cancer as it has been demonstrated that it reduces long-term recurrences and increases survivial. However, this therapy, which suppresses estrogen production and estrogen-induced effects, is associated with the development of joint pain which can significantly reduce quality of life and lead to treatment discontinuation.

The main question the study aims o answer is:

Can balneotherapy (BT) alleviate muscle-skeletal pain (primary objective) derived from endocrine therapy and improve quality of life (secondary objective) in young women with HR+ breast cancer?

Eligibility criteria

Qualifiers

None

Disqualifiers

Chronic musculoskeletal conditions predating the initiation of endocrine therapy and/or unrelated to effects derived from the endocrine therapy (i.e. fibromyalgia)

Anxiety-depression syndrome predating the initiation of endocrine therapy that is treated with drugs.

Fear of water

Fecal and/or urinary incontinence

Trial design

Treatments tested in this trial

  • Balneotherapy

Treatment groups

96 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Parc de Salut Mar

Lead sponsor

Caldes de Montbui's City Council

Collaborator

European Regional Development Fund

Collaborator

Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES)

Collaborator